Latest Conference Articles

Dr. Neal Shore Discusses ODM-201 in CRPC

Neal D. Shore, MD, FACS, medical director, Carolina Urologic Research Center, Myrtle Beach, discusses the androgen receptor inhibitor ODM-201, which is used to treat castration-resistant prostate cancer.

Dr. Tagawa on Abiraterone Plus Docetaxel in mCRPC

Scott T. Tagawa, MD, assistant professor of medicine, medical director, Genitourinary Oncology Research Program, Weill Cornell Medical College, discusses the results of a study that evaluated the safety of abiraterone acetate combined with docetaxel in patients with metastatic castration-resistant prostate cancer that were presented at the 2014 Genitourinary Cancer Symposium in San Francisco.

Long-Term Data Show Continued Improved Outcomes for Radiotherapy/Antiandrogen Combination in Locally Advanced Prostate Cancer

An updated analysis, conducted after 11 years of observation, demonstrated continued improved outcomes with the addition of radiotherapy to oral antiandrogen therapy in men with locally advanced prostate cancer.

Pre-Chemo Enzalutamide OS Benefit in mCRPC Reaches Nearly 30%

The androgen-receptor blocker enzalutamide (Xtandi) improves survival by nearly 30% in chemotherapy-naïve men with metastatic castration-resistant prostate cancer (mCRPC) and delays progression of their disease by more than 80%

ASIs Demonstrate OS Benefit in mRCC, Appear Synergistic with Anti-VEGF Therapies

A vast, pooled retrospective analysis has demonstrated that the use of ASIs may significantly improve survival outcomes in patients with mRCC.

One in Five Cancer Trials End Too Early, but GU Studies Not More Likely

The premature termination of clinical trials in the oncology setting is a problem that continues to vex researchers.

RAS Mutational Analyses in mCRC Trials Highlight Need to 'Think Beyond KRAS'

Studies presented at the 2014 GI Cancers Symposium emphasized the need for full RAS mutational analyses in the management of metastatic colorectal cancer prior to initiating treatment with anti-EGFR monoclonal antibodies.

Novel Targeted Agent Leads to Survival Benefit in HCC

Treatment with LY2157299 led to significant reductions in a prespecified biomarker that correlated with increased time to progression and overall survival in patients with advanced hepatocellular carcinoma.

Hedgehog Inhibitor Regimen Active in Advanced Pancreatic Cancer

Add-on treatment with the hedgehog pathway inhibitor vismodegib demonstrated encouraging activity in patients with untreated metastatic pancreatic ductal adenocarcinoma.

Dr. John Marshall Provides Colorectal Cancer Updates

John L. Marshall, MD, from Georgetown University Hospital, on the recent advancements in colorectal cancer.

Dr. Fine on Capecitabine Plus Temozolomide for NETs

Robert L. Fine, MD, from the Columbia University Medical Center, discusses the prospective phase II study of CAPTEM for patients with neuroendocrine tumors.

Dr. Smitha Krishnamurthi on the Phase III RAINBOW Trial

Smitha Krishnamurthi, MD, discusses the results of the RAINBOW TRIAL

High Response Rates Observed With CAPTEM in Chemo-Resistant Neuroendocrine Tumors

Data from an interim analysis of an ongoing phase II study suggest that patients with carcinoid and pituitary NETs, who have been traditionally chemo-resistant, may obtain "extraordinary responses" with capecitabine and temozolomide.

Neoadjuvant Capecitabine Considered a New Standard of Care in Rectal Cancer

Single-agent neoadjuvant capecitabine combined with radiation therapy demonstrated similar outcomes as previously established standards of care for patients with stage II or stage III rectal cancer.

Ramucirumab Combination Improves Survival in Metastatic Gastric Cancer

The combination of ramucirumab and paclitaxel resulted in a significant prolongation in survival and gains in quality of life when compared to paclitaxel alone for the second-line treatment of patients with metastatic gastric cancer.

Combined Vaccines Improve Survival in Metastatic Pancreatic Cancer

Combining two specific anti-cancer vaccines, rather than administering one as monotherapy, doubles the 1-year survival probability in patients with metastatic pancreatic ductal adenocarcinoma (PDAC), according to the results of a phase II study presented January 14.

Second-Line mCRC Data Further Support RAS Testing Before Panitumumab Use

An analysis of phase III, second-line data has shown that RAS mutations beyond KRAS exon 2 are negative predictive biomarkers for the EGFR-inhibitor panitumumab in metastatic colorectal cancer.

Dr. Garner Discusses the myRisk Hereditary Cancer Test

Elizabeth Garner, MD, MPH, vice president, Clinical Affairs, Preventive Care, Myriad Genetics, discusses the myRisk Hereditary Cancer Test.

Postneoadjuvant Bisphosphonate Benefits in Breast Cancer Linked to Age, Menopausal Status

Postneoadjuvant bisphosphonate therapy in women with residual invasive disease following chemotherapy for primary breast cancer does not improve clinical outcomes, according to an interim analysis of a large phase III clinical trial presented at the 2013 San Antonio Breast Cancer Symposium.

Dr. Esserman Discusses the I-SPY 2 Trial

Laura J. Esserman, MD, discusses the I-SPY 2 trial, a clinical trial for women with newly diagnosed, locally advanced breast cancer.

Dr. Brenner on the Link Between Breast Cancer and Obesity

Andrew J. Brenner, MD, PhD, from the Cancer Therapy Research Center, discusses the link between obesity and breast cancer outcomes.

Dr. Julie Gralow Discusses the SWOG S0500 Trial

Julie R. Gralow, MD, from the Seattle Cancer Care Alliance, discusses the SWOG S0500 trial, which evaluated different therapies for patients with metastatic breast cancer who had elevated circulating tumor cell levels.

Novel Trial Design Shows Early Value for Veliparib/Carboplatin in TNBC

The first results from the novel the I-SPY 2 trial show encouraging possibilities for a veliparib/carboplatin combination therapy in TNBC.

Ramucirumab Does Not Prolong PFS in HER2-Negative Metastatic Breast Cancer

Antiangiogenic therapy with ramucirumab, an investigational agent that binds to VEGFR-2, added to first-line docetaxel failed to delay the progression of HER2-negative metastatic breast cancer.

CTCs Prognostic But Not Helpful In Switching Therapy in MBC

Switching chemotherapy based on level of elevated circulating tumor cells after one cycle of chemotherapy did not improve OS or PFS in women with metastatic breast cancer.

Carboplatin Improves pCR More Than Bevacizumab in TNBC

The addition of carboplatin to standard neoadjuvant chemotherapy increased pathologic complete response rates in patients with triple-negative breast cancer.

Idelalisib Improves Survival in High-Risk CLL

Combination treatment with idelalisib plus rituximab was associated with a >70% improvement in OS in patients with high-risk relapsed/refractory CLL.

BOLERO-3 Safety Analysis Finds Everolimus Regimen Is Manageable

The combination of everolimus, trastuzumab, and vinorelbine, as given in the BOLERO-3 trial in patients with pretreated HER2-positive advanced breast cancer, is adequately tolerated, and adverse events are manageable.

Dr. McIntyre on Frontline Eribulin in HER2-Negative MBC

Kristi McIntyre, MD, from Texas Oncology, discusses the results of a phase II, multicenter, single-arm study that studies eribulin mesylate as first-line therapy for locally recurrent or metastatic HER2-negative breast cancer.

Dr. Matthew Ellis Discusses the FALCON Trial

Matthew J. Ellis, MD, PhD, from the Siteman Cancer Center, discusses the ongoing phase III FALCON trial.